Went public 06/06/01 at $16 per share
Filing Range: 6.7 million shares at $14 to $16
Offering Size: $100.5 million
Post Offering Valuation: $464.1 million
Shares Outstanding: 32.2 million shares
Underwriters: Salomon Smith Barney/Credit Suisse First Boston/U.S. Bancorp Piper Jaffray
Company Counsel: Skadden, Arps, Slate, Meagher & Flom
Manager Counsel: Debevoise & Plimpton
Auditor: Deloitte & Touche LLP
Provides clinical laboratory services which fall into two general classes of tests: routine and esoteric. The company’s routine or commonly ordered tests include blood cholesterol tests used in the detection of early heart disease; glucose tests to identify diabetes; blood cell measurements; PAP smears used to screen for cervical cancer; and AIDS screening. Esoteric tests, which are ordered infrequently and usually require more specialized equipment, include hepatitis and cancer markers.
Kelso & Co.
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 09/01/1998 1 Expansion 27495.0
2 11/01/1999 1 Expansion 139600.0
3 07/01/2000 1 Expansion 21094.0
(Data in $ millions except EPS)
Total Revenues: $337.5
Net Income: 41.6